Nasus Pharma Ltd SEC filings NSRX
Nasus Pharma Ltd has 100 filings in SEC EDGAR's recent list, going back to Aug 30, 2024. Its latest annual report, Form 20-F, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 8, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Oct 19, 2026 | — |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 424B5 | Prospectus supplement | Sep 18, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 18, 2026 | Sep 18, 2026 |
| 6-K | Current report (foreign issuer) | Sep 14, 2026 | Sep 14, 2026 |
| EFFECT | Filing | Sep 11, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| F-3 | Shelf registration (foreign issuer) | Sep 1, 2026 | — |
| EFFECT | Filing | Aug 20, 2026 | — |
| 6-K | Current report (foreign issuer) | Aug 19, 2026 | Aug 19, 2026 |
| POS AM | Filing | Aug 19, 2026 | — |
| 6-K | Current report (foreign issuer) | Aug 17, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 28, 2026 | Jul 28, 2026 |
| 6-K | Current report (foreign issuer) | Jun 9, 2026 | Jun 9, 2026 |
| S-8 | Employee stock plan registration | May 26, 2026 | — |
| EFFECT | Filing | Mar 31, 2026 | — |
| POS AM | Filing | Mar 27, 2026 | — |
| 6-K | Current report (foreign issuer) | Mar 25, 2026 | Mar 25, 2026 |
| 20-F | Annual report (foreign issuer) | Mar 25, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 16, 2026 | Mar 16, 2026 |
| EFFECT | Filing | Mar 13, 2026 | — |
| CORRESP | Letter to the SEC | Mar 11, 2026 | — |
| 6-K | Current report (foreign issuer) | Mar 6, 2026 | Mar 6, 2026 |
| UPLOAD | Letter from the SEC | Mar 6, 2026 | — |
| 6-K | Current report (foreign issuer) | Mar 4, 2026 | Mar 4, 2026 |
| F-1 | Registration statement (foreign issuer) | Mar 2, 2026 | — |
| D | Filing | Feb 25, 2026 | — |
| 6-K | Current report (foreign issuer) | Feb 24, 2026 | Feb 23, 2026 |
| 6-K | Current report (foreign issuer) | Feb 13, 2026 | Feb 13, 2026 |
| 6-K | Current report (foreign issuer) | Feb 12, 2026 | Feb 11, 2026 |
| 6-K | Current report (foreign issuer) | Jan 29, 2026 | Jan 29, 2026 |
| 6-K | Current report (foreign issuer) | Jan 20, 2026 | Jan 20, 2026 |
| 6-K | Current report (foreign issuer) | Dec 29, 2025 | Jun 30, 2025 |
| 6-K | Current report (foreign issuer) | Dec 22, 2025 | Dec 22, 2025 |
| 6-K | Current report (foreign issuer) | Nov 20, 2025 | Nov 20, 2025 |
| 6-K | Current report (foreign issuer) | Nov 18, 2025 | Nov 18, 2025 |
| 6-K | Current report (foreign issuer) | Nov 3, 2025 | Nov 3, 2025 |
| 6-K | Current report (foreign issuer) | Oct 8, 2025 | Oct 8, 2025 |
| 6-K | Current report (foreign issuer) | Sep 30, 2025 | Sep 30, 2025 |
| 6-K | Current report (foreign issuer) | Sep 5, 2025 | Sep 5, 2025 |
| 6-K | Current report (foreign issuer) | Aug 14, 2025 | Aug 14, 2025 |
| 424B4 | Prospectus | Aug 14, 2025 | — |
| EFFECT | Filing | Aug 12, 2025 | — |
| CERT | Nyse american certification | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| 8-A12B | Filing | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 7, 2025 | — |
| F-1/A | Filing | Aug 7, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2025 | — |
| FWP | Free writing prospectus | Jul 30, 2025 | — |
| FWP | Free writing prospectus | Jul 28, 2025 | — |
| CORRESP | Letter to the SEC | Jul 28, 2025 | — |
| F-1/A | Filing | Jul 28, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2025 | — |
| F-1 | Registration statement (foreign issuer) | Jul 9, 2025 | — |
| DRSLTR | Filing | May 21, 2025 | — |
| DRS/A | Filing | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| DRSLTR | Filing | May 12, 2025 | — |
| DRS/A | Filing | May 12, 2025 | — |
| UPLOAD | Letter from the SEC | May 7, 2025 | — |
| DRSLTR | Filing | Apr 29, 2025 | — |
| DRS/A | Filing | Apr 29, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2025 | — |
| DRSLTR | Filing | Apr 16, 2025 | — |
| DRS/A | Filing | Apr 16, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2025 | — |
| DRSLTR | Filing | Mar 21, 2025 | — |
| DRS/A | Filing | Mar 21, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2025 | — |
| DRS/A | Filing | Feb 6, 2025 | — |
| DRSLTR | Filing | Feb 5, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2025 | — |
| DRSLTR | Filing | Dec 31, 2024 | — |
| DRS/A | Filing | Dec 31, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2024 | — |
| DRS | Filing | Aug 30, 2024 | — |
Showing 78 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NSRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv - Yafo, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2029039
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.